乳腺癌分子亚型的变化与转移和无进展生存期的关系。

Breast disease Pub Date : 2024-01-01 DOI:10.3233/BD-249000
Fitran Amansyah, Prihantono Prihantono, Firdaus Hamid, Salman Ardi Syamsu, John Pieter, Muhammad Faruk
{"title":"乳腺癌分子亚型的变化与转移和无进展生存期的关系。","authors":"Fitran Amansyah, Prihantono Prihantono, Firdaus Hamid, Salman Ardi Syamsu, John Pieter, Muhammad Faruk","doi":"10.3233/BD-249000","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Molecular subtyping of breast cancer cells is increasingly being developed as an initial step in selecting therapy and predicting the prognosis of breast cancer patients. During breast cancer, the molecular subtype of cancer cells can change. This study aimed to analyze the relationship between changes in the intrinsic subtype of breast cancer with metastasis and progression-free survival in breast cancer patients.</p><p><strong>Methods: </strong>This was a retrospective cohort study of patients diagnosed with breast cancer from 2016 to 2021. The molecular subtypes from the immunohistochemical examination results were recorded twice, and metastasis and progression-free survival (PFS) were recorded. The data were analyzed using the chi-square test and SPSS 26.</p><p><strong>Results: </strong>Of the 44 patients, 19 (43.2%) experienced a change in molecular subtype, and 25 (56.8%) did not. No significant relationship existed between changes in molecular subtype and metastasis (p = 0.405). No significant relationship existed between changes in molecular subtype and PFS (p = 0.900). A significant relationship was found between changes in the molecular subtype and PFS in the patients with changes in the molecular subtype (p = 0.022).</p><p><strong>Conclusions: </strong>Changes in the intrinsic subtype were associated with PFS in breast cancer patients. Patients with an intrinsic subtype that changed to triple-negative showed worse PFS.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11091556/pdf/","citationCount":"0","resultStr":"{\"title\":\"The relationship of changes in molecular subtypes with metastases and progression-free survival in breast cancer.\",\"authors\":\"Fitran Amansyah, Prihantono Prihantono, Firdaus Hamid, Salman Ardi Syamsu, John Pieter, Muhammad Faruk\",\"doi\":\"10.3233/BD-249000\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Molecular subtyping of breast cancer cells is increasingly being developed as an initial step in selecting therapy and predicting the prognosis of breast cancer patients. During breast cancer, the molecular subtype of cancer cells can change. This study aimed to analyze the relationship between changes in the intrinsic subtype of breast cancer with metastasis and progression-free survival in breast cancer patients.</p><p><strong>Methods: </strong>This was a retrospective cohort study of patients diagnosed with breast cancer from 2016 to 2021. The molecular subtypes from the immunohistochemical examination results were recorded twice, and metastasis and progression-free survival (PFS) were recorded. The data were analyzed using the chi-square test and SPSS 26.</p><p><strong>Results: </strong>Of the 44 patients, 19 (43.2%) experienced a change in molecular subtype, and 25 (56.8%) did not. No significant relationship existed between changes in molecular subtype and metastasis (p = 0.405). No significant relationship existed between changes in molecular subtype and PFS (p = 0.900). A significant relationship was found between changes in the molecular subtype and PFS in the patients with changes in the molecular subtype (p = 0.022).</p><p><strong>Conclusions: </strong>Changes in the intrinsic subtype were associated with PFS in breast cancer patients. Patients with an intrinsic subtype that changed to triple-negative showed worse PFS.</p>\",\"PeriodicalId\":9224,\"journal\":{\"name\":\"Breast disease\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11091556/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast disease\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3233/BD-249000\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/BD-249000","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:乳腺癌细胞的分子亚型越来越多地被开发出来,作为选择治疗方法和预测乳腺癌患者预后的第一步。在乳腺癌发病过程中,癌细胞的分子亚型会发生变化。本研究旨在分析乳腺癌内在亚型的变化与乳腺癌患者转移和无进展生存期之间的关系:这是一项回顾性队列研究,研究对象为2016年至2021年确诊的乳腺癌患者。两次记录免疫组化检查结果中的分子亚型,并记录转移和无进展生存期(PFS)。数据采用卡方检验和 SPSS 26 进行分析:结果:在 44 例患者中,19 例(43.2%)的分子亚型发生了变化,25 例(56.8%)没有发生变化。分子亚型变化与转移之间无明显关系(P = 0.405)。分子亚型变化与 PFS 之间无明显关系(p = 0.900)。在分子亚型发生变化的患者中,分子亚型的变化与 PFS 之间存在明显关系(p = 0.022):结论:内在亚型的变化与乳腺癌患者的生存期有关。结论:固有亚型的变化与乳腺癌患者的生存期有关,固有亚型变为三阴性的患者生存期更短。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The relationship of changes in molecular subtypes with metastases and progression-free survival in breast cancer.

Background: Molecular subtyping of breast cancer cells is increasingly being developed as an initial step in selecting therapy and predicting the prognosis of breast cancer patients. During breast cancer, the molecular subtype of cancer cells can change. This study aimed to analyze the relationship between changes in the intrinsic subtype of breast cancer with metastasis and progression-free survival in breast cancer patients.

Methods: This was a retrospective cohort study of patients diagnosed with breast cancer from 2016 to 2021. The molecular subtypes from the immunohistochemical examination results were recorded twice, and metastasis and progression-free survival (PFS) were recorded. The data were analyzed using the chi-square test and SPSS 26.

Results: Of the 44 patients, 19 (43.2%) experienced a change in molecular subtype, and 25 (56.8%) did not. No significant relationship existed between changes in molecular subtype and metastasis (p = 0.405). No significant relationship existed between changes in molecular subtype and PFS (p = 0.900). A significant relationship was found between changes in the molecular subtype and PFS in the patients with changes in the molecular subtype (p = 0.022).

Conclusions: Changes in the intrinsic subtype were associated with PFS in breast cancer patients. Patients with an intrinsic subtype that changed to triple-negative showed worse PFS.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Breast disease
Breast disease Medicine-Oncology
CiteScore
1.80
自引率
0.00%
发文量
59
期刊介绍: The recent expansion of work in the field of breast cancer inevitably will hasten discoveries that will have impact on patient outcome. The breadth of this research that spans basic science, clinical medicine, epidemiology, and public policy poses difficulties for investigators. Not only is it necessary to be facile in comprehending ideas from many disciplines, but also important to understand the public implications of these discoveries. Breast Disease publishes review issues devoted to an in-depth analysis of the scientific and public implications of recent research on a specific problem in breast cancer. Thus, the reviews will not only discuss recent discoveries but will also reflect on their impact in breast cancer research or clinical management.
期刊最新文献
Sentinel node in breast cancer as an indicator of quality in medical care: Evaluation of statistics in Colombia. Telangiectasias induced by combination tucatinib and ado-trastuzumab emtansine in a patient with metastatic breast cancer. Clinicopathological analysis of 38 male patients diagnosed with breast cancer. Impact of the COVID-19 pandemic on breast cancer pathological stage at diagnosis in Tunisian patients. Use of axillary ultrasound to guide breast cancer management in the genomic assay era.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1